Welcome to our dedicated page for DVYSR news (Ticker: DVYSR), a resource for investors and traders seeking the latest updates and insights on DVYSR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DVYSR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DVYSR's position in the market.
On February 7, 2022, Devyser Diagnostics AB announced its acquisition of 70% of SmartSeq S.r.l. for EUR 835,000, financing the transaction with 29% cash and 71% in newly issued shares. This strategic move follows Devyser's initial 29.9% stake acquired in December 2018. The acquisition is expected to enhance Devyser's gross profit by MSEK 2-3 annually and improve its gross margin by allowing in-house software development. However, it involves a share dilution of approximately 0.5% and will consolidate from February 2022.
